Abstract: This invention relates to delivery of biologically active cargo molecules, such as polypeptides and nucleic acids, into the cytoplasm and nuclei of cells in vitro and in vivo. Intracellular delivery of cargo molecules according to this invention is accomplished by the use of novel transport polypeptides which include HIV tat protein or one or more portions thereof, and which are covalently attached to cargo molecules. The transport polypeptides in preferred embodiments of this invention are characterized by the presence of the tat basic region (amino acids 49-57), the absence of the tat cysteine-rich region (amino acids 22-36) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86) of the naturally-occurring tat protein. By virtue of the absence of the cysteine-rich region, the preferred transport polypeptides of this invention solve the potential problems of spurious trans-activation and disulfide aggregation.
Type:
Grant
Filed:
April 28, 1994
Date of Patent:
November 13, 2001
Assignees:
Whitehead Institute for Biomedical Research, Johns Hopkins Univ. School of Medicine, Biogen, Inc.
Inventors:
Alan Frankel, Carl Pabo, James G. Barsoum, Stephen E. Fawell, R. Blake Pepinsky
Abstract: Biodegradable polymers are described comprising the recurring monomeric units shown in formula I: ##STR1## wherein: R is selected from the group consisting of H, alkyl, aryl or heterocyclic; andR' is selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, heterocyclic or heterocycloxy; andn is 5 to 500,wherein said biodegradable polymer is biocompatible before and upon biodegradation.Processes for preparing the polymers, compositions containing the polymers and biologically active substances, articles useful for implantation or injection into the body fabricated from the compositions, and methods for controllably releasing biologically active substances using the polymers, are also described.
Abstract: This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.
Type:
Grant
Filed:
May 28, 1996
Date of Patent:
December 9, 1997
Assignees:
GPI NIL Holdings, Inc., Johns Hopkins Univ. School of Medicines
Inventors:
Joseph P. Steiner, Solomon Snyder, Gregory S. Hamilton
Abstract: An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, the milk mucin complex, the 46 Kd apparent MW glycoprotein, a polypeptide having the rotavirus-binding specificity of the 46 Kd apparent MW HMFG glycoprotein, mixtures thereof, or mixtures thereof, and optionally skim milk, curd, and/or whey. They product of the invention is provided also as an anti-diarrheal kit, with instructions for its use. The product of the invention has therapeutic and prophylactic application for inhibiting the onset of, or countering, rotavirus infection and/or diarrhea, in a subject, such as for example, infants and children (infantile gasteroenteritis), travellers, and immunodeficient persons, including HIV positive and transplant patients.
Type:
Grant
Filed:
January 23, 1995
Date of Patent:
April 9, 1996
Assignees:
Senomed, Inc., Cancer Research Fund of Contra Costa, The Johns Hopkins Univ. School of Medicine
Inventors:
Jerry A. Peterson, Robert H. Yolken, David S. Newburg